logo

For the Inventor, By the Inventor

Tokyo, Japan

Msd K.k.

USPTO Granted Patents = 47

% Expired Patents = 12.8



Forward Citations = 166

Loading Chart...
Loading Chart...

111 inventors (with patents filed for the assignee):

goldMedal Tsuyoshi Nagase (9 out of 15 patents)

silverMedal Toshihiro Sakamoto (8 out of 29 patents)

bronzeMedal Hidetomo Furuyama (7 out of 14 patents)

4.  Makoto Bamba (7 out of 13 patents)

5.  Nobuhiko Kawanishi (7 out of 14 patents)

6.  Nagaaki Sato (7 out of 19 patents)

7.  Satoshi Sunami (6 out of 8 patents)

8.  Kenji Niiyama (6 out of 17 patents)

9.  Keiji Takahashi (6 out of 16 patents)

10.  Mitsuru Ohkubo (6 out of 22 patents)

11.  Toshiyuki Takahashi (6 out of 24 patents)

12.  Teruyuki Nishimura (6 out of 15 patents)

13.  Tomoharu Iino (6 out of 12 patents)

14.  Yasuhiro Goto (5 out of 37 patents)

15.  Yoshio Ogino (5 out of 21 patents)


Core Competencies:
Heteroaryl Quinazoline Derivatives
Dihydropyrazolopyrimidinone Derivatives
AKT Inhibitors
Combination Cancer Therapy
Aminopyridine Derivatives
Pyridinecarboxamide Derivatives
Benzimidazole Derivatives
Spirochromanone Derivatives
Piperidine Derivatives
Sulfonyl-Substituted Derivatives
Fused Ring Compounds
Therapeutic Compounds

47 patents:

1. 8846700 - Heteroaryl quinazoline derivatives (2014-09-30),
2. 8791125 - Dihydropyrazolopyrimidinone derivatives (2014-07-29),
3. 8765789 - 2-pyridinecarboxamide derivatives (2014-07-01),
4. 8614221 - Inhibitors of Akt activity (2013-12-24),
5. 8609699 - Oxotetrahydrofuran-2-yl-benzimidazole derivative (2013-12-17),
6. 8592428 - Acetyl pyrrolidinyl indole derivative (2013-11-26),
7. 8575179 - Dihydropyrazolopyrimidinone derivatives (2013-11-05),
8. 8536193 - Inhibitors of AKT activity (2013-09-17),
9. 8524730 - Spirochromanone carboxylic acids (2013-09-03),
10. 8519136 - Aminopyridine derivatives having aurora a selective inhibitory action (2013-08-27),
11. 8507505 - Dihydropyrazolopyrimidinone derivative (2013-08-13),
12. 8492397 - Aminopyridine derivatives having Aurora A selective inhibitory action (2013-07-23),
13. 8481503 - Combination cancer therapy with an AKT inhibitor and other anticancer agents (2013-07-09),
14. 8455477 - Therapeutic compounds (2013-06-04),
15. 8436004 - Bicycloaniline derivative (2013-05-07),
Company Overview
Msd K.K., based in Tokyo, specializes in the development and manufacturing of innovative pharmaceutical solutions, particularly in oncology. The company focuses on a range of advanced compounds, including heteroaryl quinazoline derivatives and dihydropyrazolopyrimidinone derivatives, aimed at inhibiting Akt activity and enhancing combination cancer therapies. With a commitment to addressing complex medical challenges, Msd K.K. leverages its expertise in various therapeutic areas, contributing to the advancement of healthcare solutions in Japan and beyond.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Msd K.k. USPTO Patent Assignee Logo
47 Patents

#825 in Tokyo

#1,779 in Japan

#14,827 in the World

Tokyo, JP
Tokyo, Japan

Msd K.k.

Forward Citations = 166

111 inventors:

goldMedal Tsuyoshi Nagase (9 out of 15 patents)

silverMedal Toshihiro Sakamoto (8 out of 29 patents)

bronzeMedal Hidetomo Furuyama (7 out of 14 patents)

4.  Makoto Bamba (7 out of 13 patents)

5.  Nobuhiko Kawanishi (7 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Msd K.k.. Retrieved from https://idiyas.com/company/msd-k-k

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…